caketin said " They don't even buy promising products until they are well established or competing with one of their own effectively." No that's too general to be true, I watched Merck circle VLA for awhile waiting for the price to be driven down...then swooped when the cancer product wasn't even near market...they see value they will take it up, agree somewhat with the hard work $$ for clinical's but there are examples of partnerships to help startup bio's reach the end game. Here we have a product/s that do already meet the market but can't turn a $, cost blowouts are the real issue and no-one attempts to rein them in BOD wise.
News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval, page-195
-
- There are more pages in this discussion • 373 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.15 |
Change
0.000(0.00%) |
Mkt cap ! $291.2M | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.15 | $14.60 | $347.8K | 23.20K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 760 | $15.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.15 | 388 | 1 |
View Market Depth
| Last trade - 15.58pm 30/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |